Clinical Trials Logo

Citation(s)

A Phase II Trial of Weekly Docetaxel and Bortezomib (Velcade; PS-341) in the Treatment of Patients With Advanced Hormone-Refractory Prostate Cancer

Details for clinical trial NCT00193232